Anaesthesia Choice for Creation of Arteriovenous Fistula (ACCess) study protocol : a randomised controlled trial comparing primary unassisted patency at 1 year of primary arteriovenous fistulae created under regional compared to local anaesthesia
Alan Jr Macfarlane,Rachel J Kearns,Marc James Clancy,David Kingsmore,Karen Stevenson,Andrew Jackson,Patrick Mark,Margaret Aitken,Ramani Moonesinghe,Cecilia Vindrola-Padros,Lucian Gaianu,Gavin Pettigrew,Reza Motallebzadeh,Nikolaos Karydis,Alex Vesey,Rita Singh,Thalakunte Muniraju,Stuart Suttie,Alex McConnachie,Kirsty Wetherall,Kariem El-Boghdadly,Rosemary Hogg,Iain Thomson,Vishal Nangalia,Emma Aitken,Access collaborative group,ACCess collaborative group,Regin Lagaac,Rosie Hogg,Andrew Dalton,Samira Bell,Rose Ross,David McNair,Linda Stiff,Catherine Jardine,Mohammed Tariq Dosani,Jennifer Sainsbury,Kiran Sran,Nadia Castrillo,James Gilbert,Sanjay Sinha,Sheera Sutherland,Sarah Crosbie,Madita Gavrila,Sandra Montgomery,Tina McLennan,Nina Tarkowska,Scott Oliver,Liz Brown,Shelley McLachlan,Jonathan de Siqueira,Max Troxler,Nikki Dewhirst,Mark Wright,Chetan Srinath,Philip Bennett,Darren Morrow,Marc Clancy,Vashist Deelchand,Rani Badhan,Rajesh Sivaprakasam,Gareth Ackland TimEgan,Matt Wikner,Alan Macfarlane,Rachel Kearns,Alex MacConnachie,Ramani Moonsinghe,Cecilia Vindrola
DOI: https://doi.org/10.1136/bmjopen-2021-052188
IF: 3.006
2021-12-22
BMJ Open
Abstract:Introduction: Arteriovenous fistulae (AVF) are the 'gold standard' vascular access for haemodialysis. Universal usage is limited, however, by a high early failure rate. Several small, single-centre studies have demonstrated better early patency rates for AVF created under regional anaesthesia (RA) compared with local anaesthesia (LA). The mechanistic hypothesis is that the sympathetic blockade associated with RA causes vasodilatation and increased blood flow through the new AVF. Despite this, considerable variation in practice exists in the UK. A high-quality, adequately powered, multicentre randomised controlled trial (RCT) is required to definitively inform practice. Methods and analysis: The Anaesthesia Choice for Creation of Arteriovenous Fistula (ACCess) study is a multicentre, observer-blinded RCT comparing primary radiocephalic/brachiocephalic AVF created under regional versus LA. The primary outcome is primary unassisted AVF patency at 1 year. Access-specific (eg, stenosis/thrombosis), patient-specific (including health-related quality of life) and safety secondary outcomes will be evaluated. Health economic analysis will also be undertaken. Ethics and dissemination: The ACCess study has been approved by the West of Scotland Research and ethics committee number 3 (20/WS/0178). Results will be published in open-access peer-reviewed journals within 12 months of completion of the trial. We will also present our findings at key national and international renal and anaesthetic meetings, and support dissemination of trial outcomes via renal patient groups. Trial registration number: ISRCTN14153938. Sponsor: NHS Greater Glasgow and Clyde GN19RE456, Protocol V.1.3 (8 May 2021), REC/IRAS ID: 290482.